H. Lundbeck A/S
- Country
- π©π°Denmark
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 5.6K
- Market Cap
- -
- Website
- http://www.lundbeck.com
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
- Conditions
- Healthy Participants
- Interventions
- Drug: Lu AG06466
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 8
- Registration Number
- NCT05219838
- Locations
- πΊπΈ
Invicro, LLC, New Haven, Connecticut, United States
A Study Investigating Lu AG06466 in Healthy Men
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-Lu AG06466
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 6
- Registration Number
- NCT05201092
- Locations
- π¬π§
LabCorp Clinical Research Unit Ltd, Leeds, United Kingdom
Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Lu AG06466Drug: Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05177029
- Locations
- π―π΅
P-One Clinic, Keikokai Medical Corporation, Yokamachi Hachioji City, Tokyo, Japan
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05164172
- Locations
- πΊπΈ
Children's Wisconsin - Milwaukee Campus, Milwaukee, Wisconsin, United States
πΉπ·Eskisehir Osmangazi Universitesi Tip Fakultesi Hastanesi, Eskisehir, Turkey
πΊπΈKi Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States
A Study Investigating Lu AG22515 in Healthy Adults
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 58
- Registration Number
- NCT05136053
- Locations
- πΊπΈ
Frontage Clinical Research Inc, Secaucus, New Jersey, United States
πΊπΈCenExel CNS, Long Beach, California, United States
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 237
- Registration Number
- NCT05133323
- Locations
- πΊπΈ
Excell Research - ClinEdge - PPDS, Oceanside, California, United States
πΊπΈUNISON Clinical Trials (Shahram Jacobs md inc.), Sherman Oaks, California, United States
πΊπΈAllied Biomedical Research Institute, Miami, Florida, United States
A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 30
- Registration Number
- NCT05126316
- Locations
- π¬π§
St Pancras Clinical Research, London, United Kingdom
π¬π§Medicines Evaluation Unit, Manchester, United Kingdom
A Study of Lu AF82422 in Participants With Multiple System Atrophy
- Conditions
- Multiple System Atrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 64
- Registration Number
- NCT05104476
- Locations
- πΊπΈ
The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
πΊπΈUniversity of California - San Diego, La Jolla, California, United States
πΊπΈUCSF Memory and Aging Center, San Francisco, California, United States
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
- Conditions
- Focal Epilepsy
- Interventions
- Drug: Lu AG06466Drug: Placebo
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 1
- Registration Number
- NCT05081518
- Locations
- πΊπΈ
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05074459
- Locations
- πΊπΈ
Labcorp Clinical Research Unit, Inc., Madison, Wisconsin, United States